m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00205)
Target Name Cyclin-A2 (CCNA2)
Synonyms
Cyclin-A; Cyclin A; CCN1; CCNA
    Click to Show/Hide
Gene Name CCNA2
Chromosomal Location 4q27
Family cyclin family; Cyclin AB subfamily
Function
Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle.
    Click to Show/Hide
Gene ID 890
Uniprot ID
CCNA2_HUMAN
HGNC ID
HGNC:1578
Ensembl Gene ID
ENSG00000145386
KEGG ID
hsa:890
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CCNA2 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line Cerebral cortex Mus musculus
Treatment: METTL3 (f/f, Emx1-cre) cerebral cortex
Control: Wild type cerebral cortex
 GSE154992
Regulation
logFC: 7.89E-01
p-value: 6.22E-11
More Results Click to View More RNA-seq Results
In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Target Regulation Up regulation
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Responsed Drug Epigallocatechin gallate Phase 3
 Drug Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary FTO knockdown markedly decreased the expression of Cyclin-A2 (CCNA2) and CDK2, crucial cell cycle regulators, leading to delayed entry of MDI-induced cells into G2 phase. m6A-binding protein YTHDF2 recognized and decayed methylated mRNAs of CCNA2 and CDK2, leading to decreased protein expression, thereby prolonging cell cycle progression and suppressing adipogenesis. The adipocyte life cycle, including proliferation and adipogenesis, has become a potential target for many bioactive compounds and drugs for the prevention and treatment of obesity.
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
Arrest cell cycle at S phase
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
YTH domain-containing family protein 2 (YTHDF2) [READER]
 Regulator Info 
In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Target Regulation Down regulation
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Responsed Drug Epigallocatechin gallate Phase 3
 Drug Info 
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary FTO knockdown markedly decreased the expression of Cyclin-A2 (CCNA2) and CDK2, crucial cell cycle regulators, leading to delayed entry of MDI-induced cells into G2 phase. m6A-binding protein YTHDF2 recognized and decayed methylated mRNAs of CCNA2 and CDK2, leading to decreased protein expression, thereby prolonging cell cycle progression and suppressing adipogenesis. The adipocyte life cycle, including proliferation and adipogenesis, has become a potential target for many bioactive compounds and drugs for the prevention and treatment of obesity.
Target Regulation Down regulation
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
Arrest cell cycle at S phase
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Obesity [ICD-11: 5B81]
 Disease Info 
In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Responsed Disease Obesity [ICD-11: 5B81]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Epigallocatechin gallate Phase 3
 Drug Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 2 Reporting the m6A-centered Disease Response [2]
Response Summary FTO knockdown markedly decreased the expression of Cyclin-A2 (CCNA2) and CDK2, crucial cell cycle regulators, leading to delayed entry of MDI-induced cells into G2 phase. m6A-binding protein YTHDF2 recognized and decayed methylated mRNAs of CCNA2 and CDK2, leading to decreased protein expression, thereby prolonging cell cycle progression and suppressing adipogenesis. The adipocyte life cycle, including proliferation and adipogenesis, has become a potential target for many bioactive compounds and drugs for the prevention and treatment of obesity.
Responsed Disease Obesity [ICD-11: 5B81]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
Arrest cell cycle at S phase
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 3 Reporting the m6A-centered Disease Response [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Responsed Disease Obesity [ICD-11: 5B81]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Epigallocatechin gallate Phase 3
 Drug Info 
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 4 Reporting the m6A-centered Disease Response [2]
Response Summary FTO knockdown markedly decreased the expression of Cyclin-A2 (CCNA2) and CDK2, crucial cell cycle regulators, leading to delayed entry of MDI-induced cells into G2 phase. m6A-binding protein YTHDF2 recognized and decayed methylated mRNAs of CCNA2 and CDK2, leading to decreased protein expression, thereby prolonging cell cycle progression and suppressing adipogenesis. The adipocyte life cycle, including proliferation and adipogenesis, has become a potential target for many bioactive compounds and drugs for the prevention and treatment of obesity.
Responsed Disease Obesity [ICD-11: 5B81]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
Arrest cell cycle at S phase
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Epigallocatechin gallate [Phase 3]
 Drug Info 
In total 2 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
Experiment 2 Reporting the m6A-centered Drug Response [1]
Response Summary m6A-dependent Cyclin-A2 (CCNA2) and CDK2 expressions mediated by FTO and YTHDF2 contributed to EGCG-induced adipogenesis inhibition.
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Obesity ICD-11: 5B81
 Disease Info 
Cell Process Adipogenesis
In-vitro Model 3T3-L1 Normal Mus musculus CVCL_0123
References
Ref 1 Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA m(6)A-YTHDF2-dependent manner. Int J Obes (Lond). 2018 Jul;42(7):1378-1388. doi: 10.1038/s41366-018-0082-5. Epub 2018 May 24.
Ref 2 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.